Summit Therapeutics plc (SMMT) News
Filter SMMT News Items
SMMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SMMT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SMMT News From Around the Web
Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMIAMI, January 07, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will present a corporate overview and an update on the progress of our organization, including the d |
Prediction: These 3 Healthcare Stocks Will Soar in 2025Here's why they chose Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Summit Therapeutics (NASDAQ: SMMT). David Jagielski (Amgen): Shares of Amgen started crashing in late November following the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide. |
Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now?We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs. Much of this […] |
3 Stocks That Could Be Monster Winners in 2025Three Motley Fool contributors think they have found stocks that could provide a big bang for growth investors. Here's why they believe Novo Nordisk (NYSE: NVO), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) could be monster winners for 2025. David Jagielski (Novo Nordisk): It's been a tough 2024 for drugmaker Novo Nordisk. |
Is Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024?We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, […] |
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday?We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other stocks that jumped yesterday. Broader indices haven’t been performing very well since the Fed’s not so surprise revelation about the number of expected […] |
Where Will Summit Therapeutics Be in 5 Years?Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. It doesn't have a single drug on the market, yet it boasts a market capitalization of $14 billion. Finding clinical-stage biotechs with market caps above $10 billion is rare. |
3 Stocks That Could Turn $1,000 into $5,000 by 2030Moderna's (NASDAQ: MRNA) market cap currently stands at around $14.8 billion. To become a five-bagger, the messenger RNA (mRNA) pioneer would need to grow its market cap to $74 billion. The good news for Moderna is that it's already proven it can reach that level. |
3 No-Brainer Biotech Stocks to Buy With $200 Right NowHere are three no-brainer biotech stocks to buy with $200 right now. Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere. You can scoop up a share of BioNTech for less than $120 at the time of this writing. |
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall StreetIt's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst Justin Zelin thinks Viking Therapeutics stock can reach $125 per share for a gain of about 166% over the next 12 months. If an experimental weight loss treatment it's developing continues to succeed in clinical trials, the stock could more than double again. |